- Home
- AIFF vs IBIO Comparison
AIFF vs IBIO Comparison
Compare AIFF & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- IBIO
- Stock Information
- Founded
- AIFF 2006
- IBIO 2008
- Country
- AIFF Canada
- IBIO United States
- Employees
- AIFF N/A
- IBIO N/A
- Industry
- AIFF
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- IBIO Health Care
- Exchange
- AIFF NYSE
- IBIO Nasdaq
- Market Cap
- AIFF 26.6M
- IBIO 24.3M
- IPO Year
- AIFF N/A
- IBIO N/A
- Fundamental
- Price
- AIFF $2.33
- IBIO $2.48
- Analyst Decision
- AIFF
- IBIO Strong Buy
- Analyst Count
- AIFF 0
- IBIO 3
- Target Price
- AIFF N/A
- IBIO $4.87
- AVG Volume (30 Days)
- AIFF 59.4K
- IBIO 104.4K
- Earning Date
- AIFF 11-14-2024
- IBIO 02-07-2025
- Dividend Yield
- AIFF N/A
- IBIO N/A
- EPS Growth
- AIFF N/A
- IBIO N/A
- EPS
- AIFF N/A
- IBIO N/A
- Revenue
- AIFF $74,000.00
- IBIO $175,000.00
- Revenue This Year
- AIFF N/A
- IBIO N/A
- Revenue Next Year
- AIFF N/A
- IBIO N/A
- P/E Ratio
- AIFF N/A
- IBIO N/A
- Revenue Growth
- AIFF N/A
- IBIO 250.00
- 52 Week Low
- AIFF $2.32
- IBIO $1.02
- 52 Week High
- AIFF $15.90
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- AIFF 32.31
- IBIO 48.23
- Support Level
- AIFF $2.89
- IBIO $2.26
- Resistance Level
- AIFF $3.25
- IBIO $2.75
- Average True Range (ATR)
- AIFF 0.28
- IBIO 0.23
- MACD
- AIFF -0.07
- IBIO -0.02
- Stochastic Oscillator
- AIFF 0.93
- IBIO 36.36
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.